×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Amgen Opens New Affiliate in Taiwan

Amgen announced on May 31, 2016, that the Company has opened an affiliate in Taiwan, headquartered in Taipei. Speakers at the event included Fu-Kuen Lin, Taiwan-born inventor of Amgen’s first medicine; Desmond Padhi, Amgen vice president of Medical Sciences; Penny Wan, vice president and general manager of Amgen’s Japan Asia Pacific Region; and Kelvin Chen, general manager of Amgen’s new Taiwan affiliate.

Amgen is focused on delivering its late-stage pipeline of potential new medicines to patients around the world. Amgen’s entry into Taiwan is expected to bring more clinical trials and new treatments for grievous illness to patients in Taiwan. For Amgen, it is an important step in the Company’s global expansion efforts.

Amgen appointed Kelvin Chen as the general manager of Amgen Taiwan in the fourth quarter of 2015.

“Amgen is delighted to be establishing an affiliate in Taiwan, where abundant resources are invested in the biotechnology industry, and where the government has stated its interest in cultivating the industry,” Chen said. “As a biotechnology pioneer, Amgen will be committed to expanding treatment options for both patients and healthcare providers while striving to serve patients by developing and delivering innovative therapeutics.”

To learn more, visit amgen.com.tw .